SUBSCRIBE
SUBSCRIBE
Lone Star Bio

Kidney Cancer Vaccine Shows No Boost in Survival in M. D. Anderson Cancer Center Study

July 7, 2008 | 
1 min read

HealthDay News -- The new vaccine vitespen didn’t increase recurrence-free survival among kidney cancer patients who’d had surgery, say U.S. researchers.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Merck KGaA signage at its headquarters in Darmstadt, Germany
Business
Merck KGaA, Caris Sign Potential $1.4B Deal to Develop First-in-Class ADCs for Cancer
April 4, 2024
 · 
2 min read
 · 
Tyler Patchen
A park in Houston with skyscrapers in the backgrou
Drug Development
Biotech Accelerator Debuts in Houston
October 18, 2023
 · 
3 min read
 · 
Charlotte LoBuono